IL6 and diabetes mellitus: Thus, 16.2% (103 out of 634) of patients with DM needed an IL-6 antagonist as compared to those without DM, 7.3% of whom (246 out of 3351) required Tocilizumab (Chi 2 = 52.89; p = 0.001) (Table 6).